Adlai Nortye (ANL) Corporate Presentation summary

Pipeline and research overview

• Advancing first-in-class and best-in-class preclinical assets, including AN8025 and AN9025, with IND filings expected in 2025.

• Global R&D and clinical operations span the U.S. and China, supporting a robust oncology pipeline.

• Pipeline includes multi-functional T cell/APC modulators, pan-RAS inhibitors, and oral PD-L1 inhibitors targeting advanced solid tumors.

• Multiple assets are progressing through clinical and preclinical stages, with key data readouts and updates anticipated by year-end 2025.

AN8025: Multi-functional T cell/APC modulator

• AN8025 targets PD-L1, Lag3v, and CD86v, activating APCs and reactivating T cells for anti-tumor immunity.

• Demonstrates superior T-cell activation and tumor cell killing compared to existing checkpoint inhibitors.

• Shows potent anti-tumor activity in vivo and favorable PK/safety in non-human primates.

• IND filing expected mid-2025, with multiple registrational trials planned.

AN9025: Oral pan-RAS (ON) inhibitor

• AN9025 exhibits strong, sustained binding to CypA and RAS (ON) proteins, outperforming RMC-6236 in potency and duration.

• Achieves deeper tumor regression and more durable RAS pathway inhibition in preclinical models.

• Demonstrates approximately 100-fold greater potency in RAS mutant cell lines versus RMC-6236.

• IND filing targeted for 2H 2025.